Undoubtedly, developing a drug specifically targeting P300 functions in the regulation gluconeogenic gene expression and insulin signaling is of importance in the treatment of T2D and obesity. This evidence concerns the gene INS and obesity due to melanocortin 4 receptor deficiency.